Bitterman Robert J 4

What Happened Robert J. Bitterman — Chairman, President & CEO and a director of Phio Pharmaceuticals (PHIO) — was granted 120,000 restricted stock units (RSUs) on February 5, 2026. The Form 4 reports an acquisition (award) of 120,000 shares at $0.00 per share (no cash paid at grant). Footnote F1 states these RSU shares will vest on the first annual anniversary of the grant.

Key Details

• Transaction date: 2026-02-05 (reported on Form 4 filed 2026-02-06). No late filing indicated in the provided data.
• Transaction type/code: Award/Grant (A) of RSUs. Price reported: $0.00 per share.
• Shares awarded: 120,000 RSUs (convertible to common stock upon vesting per F1).
• Shares owned after transaction: Not disclosed in the excerpt provided. Footnote F2 notes that reported ownership typically includes shares underlying unvested RSUs.
• Filing accession: 0001683168-26-000803.

Context RSUs are a form of compensation that convert into company shares when they vest; they do not represent immediately tradable common stock until vesting occurs. This filing reports an award rather than an open-market purchase or sale, so it reflects compensation rather than a direct market vote by the insider. For the exact post-grant beneficial ownership and any further conditions, check the full Form 4 filing.